ChemRar High-Tech Center:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ChemRar High-Tech Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10656
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ロシア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ChemRar High-Tech Center (CHTC) is a developer of drugs for life-threatening diseases. The company offers drugs for the treatment of cancer, central nervous system, infectious, metabolic and cardiovascular diseases. It also offers pre-clinical and clinical research of new molecules including screening and identification of the important biological targets for new molecules, synthesis and research of new molecules, and manufacturing. CHTC also invests in companies with drug candidates in early development stage. The company serves its clients in Japan and Russia. CHTC is headquartered in Khimki, Russia.

ChemRar High-Tech Center – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemRar High-Tech Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ChemRar High-Tech Center, Medical Devices Deals, 2012 to YTD 2018 9
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
ChemDiv Enters into Co-Development Agreement with Context Therapeutics and Torrey Pines Investment 12
Regen BioPharma Enters into Agreement with ChemDiv 13
Janssen Research & Development Enters into Agreement with ChemDiv 14
ChemDiv, Torrey Pines Investment and DZNE Enter into Research Agreement 15
ChemDiv and Insilico Medicine Enter into Collaboration Agreement 16
National Immunobiological Forms Joint Venture with ChemRar HTC 17
ChemDiv Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 18
ChemRar High Tech Center Enters into Agreement with Lancet to Develop Novel Drugs in Russia 19
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 20
Dompe Farmaceutici Enters Into Co-Development Agreement With SatRx For Reparixin 21
MIPT, Wi2 And ChemDiv Research Institute Partner To Develop Therapeutics For Human Health 22
Coare Biotech Enters Into Agreement With ChemDiv To Offer Gene-To-Clinic Services 23
ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 24
Licensing Agreements 25
Pfizer Enters Into Licensing Agreement With SatRx For PF-00734200 25
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 26
Equity Offering 27
Viriom Raises USD2.35 Million in Private Placement of Shares 27
ChemRar High-Tech Center – Key Competitors 28
ChemRar High-Tech Center – Key Employees 29
ChemRar High-Tech Center – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Joint Venture 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Key Facts 2
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemRar High-Tech Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemRar High-Tech Center, Deals By Therapy Area, 2012 to YTD 2018 8
ChemRar High-Tech Center, Medical Devices Deals, 2012 to YTD 2018 9
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ChemDiv Enters into Co-Development Agreement with Context Therapeutics and Torrey Pines Investment 12
Regen BioPharma Enters into Agreement with ChemDiv 13
Janssen Research & Development Enters into Agreement with ChemDiv 14
ChemDiv, Torrey Pines Investment and DZNE Enter into Research Agreement 15
ChemDiv and Insilico Medicine Enter into Collaboration Agreement 16
National Immunobiological Forms Joint Venture with ChemRar HTC 17
ChemDiv Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 18
ChemRar High Tech Center Enters into Agreement with Lancet to Develop Novel Drugs in Russia 19
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 20
Dompe Farmaceutici Enters Into Co-Development Agreement With SatRx For Reparixin 21
MIPT, Wi2 And ChemDiv Research Institute Partner To Develop Therapeutics For Human Health 22
Coare Biotech Enters Into Agreement With ChemDiv To Offer Gene-To-Clinic Services 23
ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 24
Pfizer Enters Into Licensing Agreement With SatRx For PF-00734200 25
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 26
Viriom Raises USD2.35 Million in Private Placement of Shares 27
ChemRar High-Tech Center, Key Competitors 28
ChemRar High-Tech Center, Key Employees 29
ChemRar High-Tech Center, Subsidiaries 30
ChemRar High-Tech Center, Joint Venture 31

List of Figures
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemRar High-Tech Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ChemRar High-Tech Center, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[ChemRar High-Tech Center:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Citibank NA:企業の戦略・SWOT・財務情報
    Citibank NA - Strategy, SWOT and Corporate Finance Report Summary Citibank NA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Bestway Holdings Limited:企業の戦略・SWOT・財務情報
    Bestway Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bestway Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • EQT Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    EQT Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary EQT Corp (EQT) is an integrated oil and gas company. It operates production fields in Marcellus, Upper Devonian, Ohio Utica and other plays in Appalachian Basin. The company produces and markets natural gas …
  • ORIX Corporation:企業のM&A・事業提携・投資動向
    ORIX Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ORIX Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Iron Mountain Incorporated:企業の戦略・SWOT・財務情報
    Iron Mountain Incorporated - Strategy, SWOT and Corporate Finance Report Summary Iron Mountain Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Suelopetrol CA SACA:企業の戦略的SWOT分析
    Suelopetrol CA SACA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • LIC of India:企業の戦略・SWOT・財務情報
    LIC of India - Strategy, SWOT and Corporate Finance Report Summary LIC of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Macfarlane Group Plc (MACF):企業の財務・戦略的SWOT分析
    Macfarlane Group Plc (MACF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Emmaus Life Sciences Inc (EMMA):企業の財務・戦略的SWOT分析
    Emmaus Life Sciences Inc (EMMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • NextPharma Technologies Holding Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary NextPharma Technologies Holding Ltd (NextPharma) is a contract development and manufacturing organization that provides pharmaceutical products and services. The company offers wide range of services such as pharmaceutical development, analytical services, clinical trials services, commercia …
  • Computershare Limited (CPU):企業の財務・戦略的SWOT分析
    Computershare Limited (CPU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • 3D Systems Corporation:企業の戦略・SWOT・財務情報
    3D Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary 3D Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Albumedix AS-製薬・医療分野:企業M&A・提携分析
    Summary Albumedix A/S (Albumedix), a subsidiary of Novozymes A/S, is a developer of albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Its product Recombumin is a recombinant human albumin used in the manufacture of …
  • Exiqon AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Exiqon AS (Exiqon), a subsidiary of Qiagen NV, is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company provides product categories such as microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reag …
  • Cooper-Standard Holdings Inc.:企業の戦略・SWOT・財務分析
    Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Institut Pasteur-製薬・医療分野:企業M&A・提携分析
    Summary Institut Pasteur is a non-profit foundation that provides research, health services and education. The institute offers research in the areas of biology, genomes and genetics, immunology, infection and epidemiology, microbiology, neuroscience, parasitology and mycology, structural biology an …
  • Asseco Business Solutions SA (ABS):企業の財務・戦略的SWOT分析
    Asseco Business Solutions SA (ABS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Aethlon Medical Inc (AEMD):企業の財務・戦略的SWOT分析
    Aethlon Medical Inc (AEMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • CJ HealthCare Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary CJ HealthCare Corp (CJ HealthCare), a subsidiary CJ CheilJedang Corp, is a provider of active pharmaceutical ingredients, OTC drugs and pharmaceutical medicines. The company’s portfolio includes biologicals, antibiotics, anti cancer, parenteral nutrition, total parenteral nutrition products. …
  • Iconic Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Iconic Therapeutics Inc (Iconic Therapeutics) is a biopharmaceutical company that provides translation of scientific insight into breakthrough medicines. The company offers development of tissue factor in angiogenesis, inflammation, and metastasis that led to develop new approach to retinal …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆